We developed a new technology for enzymatic production of high quality, long and even functionalized DNA molecules, which will have a huge impact on industrial synthetic biology, precision diagnostics, therapeutics and nanotechnology.
DNA oligonucleotides are commonly synthesized by solid phase, but after decades of fine-tuning and improvements in liquid handling, the upper limit of phosphoramidite-based oligo synthesis is now about 200-300 nucleotides, with further limitations in terms of purity and efficacy in presence of strong secondary structures or repeats.
The advances and improvements in diagnostic and therapeutic systems based on nucleic acids are leading to a big and urgent need of highly pure and long DNA strands, and Moligo Technologies mission is to satisfy this necessity. In fact, thanks to our know-how, and to the capacity of experienced scientific and executive team, we are already able to synthesize, and very soon commercialize, single stranded oligonucleotides of thousands of bases with purity of about 99.9%.
Company Details
- Employees
- 13
- Founded
- -
- Address
- Nanna Svartz Väg 2, Solna,stockholm County 171 65,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- moligotechnologies.com
- HQ
- Solna, Stockholm County
Moligo Technologies Questions
Moligo Technologies's website is moligotechnologies.com
Moligo Technologies's LinkedIn profile is https://se.linkedin.com/company/moligo-technologies
Moligo Technologies has
13 employees.
View email and phone details for 13
employees at Moligo Technologies.
Moligo Technologies's industry is
Biotechnology Research
Moligo Technologies's top competitors are
Rarity Bioscience,
Aplex Bio,
Navinci,
Pixelgen Technologies,
Biolamina,
Countagen,
Molecular Attraction Ab,
Pelago Bioscience Ab,
Symcel,
Moleculent.
Moligo Technologies's categories are Biotechnology Research
Moligo Technologies's founding year is 2019
